Irish Prostate Cancer Outcomes Research (IPCOR) registry: cohort profile.

Autor:	Gordon N; UCD School of Medicine and UCD Conway Institute, University College Dublin, Dublin, Ireland noa.gordon1@ucd.ie., Dooley C; UCD School of Medicine and UCD Conway Institute, University College Dublin, Dublin, Ireland., Murphy Á; UCD School of Medicine and UCD Conway Institute, University College Dublin, Dublin, Ireland., Farooq W; UCD School of Medicine and UCD Conway Institute, University College Dublin, Dublin, Ireland., Sullivan F; University of Galway, Galway, Ireland., McDermott R; Tallaght University Hospital, Dublin, Ireland.; St Vincent's University Hospital, Dublin, Ireland., Sharp L; Population Health Sciences Institute, Newcastle University, Newcastle, UK., Watson W; UCD School of Medicine and UCD Conway Institute, University College Dublin, Dublin, Ireland., Galvin D; UCD School of Medicine and UCD Conway Institute, University College Dublin, Dublin, Ireland.; St Vincent's University Hospital, Dublin, Ireland.; Mater Misericordiae University Hospital, Dublin, Ireland.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2024 Dec 02; Vol. 14 (12), pp. e090207. Date of Electronic Publication: 2024 Dec 02.
DOI:	10.1136/bmjopen-2024-090207
Abstrakt:	Purpose: To describe the Irish Prostate Cancer Outcomes Research (IPCOR) registry. The cohort was collected to inform and improve the prostate cancer journey of men in Ireland. Participants: Established in 2015, IPCOR was a unique large-scale prospective cohort study registering men with prostate cancer in Ireland. From 2016 to 2020, IPCOR collected data on 6816 men who were newly diagnosed with prostate cancer across 16 hospitals, both public and private. A comprehensive clinical dataset was collected, capturing detailed information on men's diagnosis, treatments and follow-up. In addition, a subset of 873 men completed patient-reported outcome measures. Findings to Date: The IPCOR study has revealed several key insights into prostate cancer diagnosis and treatment in Ireland. The data indicate a high rate of diagnosis through opportunistic Prostate-Specific Antigen screening, with many cases identified at an early stage. Future Plans: IPCOR invites collaboration from the global cancer research community to use this resource to advance prostate cancer research and improve patient outcomes worldwide. IPCOR aims to continue updating long-term survival follow-up data for this cohort. It also plans to continue its collaborative approach with patients, engaging with the Lived Experience Advisory Panel in interpreting results emerging from this dataset. Moving forward, IPCOR is planning its next phase of the project, IPCOR 2.0. This will be a prospective, longitudinal, multi-centre clinical quality registry and biorepository. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu